| Previous Close | 84.74 |
| Open | 83.74 |
| Bid | 81.86 x 300 |
| Ask | 81.87 x 500 |
| Day's Range | 80.77 - 84.40 |
| 52 Week Range | 64.18 - 86.72 |
| Volume | 8,855,021 |
| Avg. Volume | 3,546,585 |
| Market Cap | 86.21B |
| Beta | 0.17 |
| PE Ratio (TTM) | 39.63 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 2.08 (2.46%) |
| Ex-Dividend Date | 2017-08-11 |
| 1y Target Est | N/A |
- Investor's Business Daily•38 minutes ago
Eli Lilly Tumbles On Arthritis Drug Delay, Light Q2 Sales
A delay in getting its rheumatoid arthritis drug to market by at least 18 months sent Eli Lilly shares lower Tuesday.
- Zacks•46 minutes ago
3 Buy-Ranked Stocks That Just Crushed Earnings
These earnings reports not only demonstrate the past quarter???s solid performance, but they also preview its financial outlook over its next operational quarter.
- Barrons.com•2 hours ago
Eli Lilly: What the Heck Just Happened?
Eli Lilly (LLY) beat earnings forecasts today, but all anyone wants to talk about is a delayed filing for its the rheumatoid arthritis drug it's developing with Incyte (INCY). Eli Lilly reported an adjusted profit of $1.11, topping the Street consensus for $1.05, on sales of $5.82 billion, above expectations for $5.59 billion. Unfortunately, Eli Lilly and Incyte announced that their resubmission of a New Drug Application for their rheumatoid arthritis drug, baricitinib, would be delayed.
